Temocillin
Sponsors
Assistance Publique Hopitaux De Paris, Fundacion Publica Andaluza Para La Gestion De La Investigacion En Salud De Sevilla, Belpharma s.a., Université Catholique de Louvain, University Hospital, Grenoble
Conditions
Antibacterial AgentsBacteremiaDrug MonitoringInfectionInfections due to EnterobacteriaceaeInfections, BacterialInfectious DiseaseIntensive Care
Phase 3
Temocillin Versus a Carbapenem as Initial Intravenous Treatment for ESBL Related Urinary Tract Infections
CompletedNCT03543436
Start: 2019-01-04End: 2020-12-14Updated: 2025-11-20
Temocillin vs Meropenem for the Targeted Treatment of Bacteraemia Resistant to Third Gen Cephalosporins
CompletedNCT04478721
Start: 2020-12-15End: 2024-12-26Updated: 2026-01-23
COTRIVAP - Efficacy of cotrimoxazole as a de-escalation treatment of Ventilator-Associated Pneumonia in intensive care unit. Multicentric non-inferiority randomised controlled trial
CompletedCTIS2023-505108-52-00
Start: 2023-12-20End: 2025-09-19Target: 628Updated: 2025-04-23
Temocillin versus meropenem for the targeted treatment of bacteraemia due to third-generation
cephalosporin-resistant Enterobacterales (ASTARTÉ):randomised, pragmatic trial
CompletedCTIS2023-508440-21-00
Start: 2024-05-21End: 2024-12-26Target: 334Updated: 2024-10-01
Phase 4
Temocillin Use in Complicated Urinary Tract Infections Due to Extended Spectrum Beta-Lactamases (ESBL)/AmpC Enterobacteriaceae
WithdrawnNCT01543347
Start: 2012-02-29End: 2012-11-30Updated: 2013-01-29
Temocillin Pharmacokinetics in Paediatrics
NCT02260102
Start: 2016-02-17End: 2022-12-31Target: 45Updated: 2022-05-31
Efficacy of Temocillin in Urinary Tract Infection Due to ESBL Producing and AmpC Hyperproducing Enterobacteriaceae
NCT02681263
Start: 2016-04-30End: 2018-09-30Updated: 2018-06-06
Disturbance of the Intestinal Microbiota by Temocillin vs Cefotaxime in Treatment of Febrile Urinary Tract Infections
CompletedNCT02959957
Start: 2016-05-20End: 2019-08-31Updated: 2019-09-16